GFAP and myeloid sarcoma: Similar work was reproduced in a larger multicenter international collaborative study where MOG and AQP4 antibodies and markers of damage myelin (i.e., MBP) and astrocytes (i.e., GFAP) were evaluated in the CSF of patients with NMOSD and MS.